Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1592/phco.24.8.819.36075 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lessons learned from a pay-for-performance scheme for appropriate prescribing using electronic health records from general practices in the Netherlands.
Health Policy
November 2024
Netherlands Institute for Health Services Research (NIVEL), Utrecht, the Netherlands.
Introduction: A nationwide pay-for-performance (P4P) scheme was introduced in the Netherlands between 2018 and 2023 to incentivize appropriate prescribing in general practice. Appropriate prescribing was operationalised as adherence to prescription formularies and measured based on electronic health records (EHR) data. We evaluated this P4P scheme from a learning health systems perspective.
View Article and Find Full Text PDFGetting the Price Right: Lessons for Medicare Price Negotiation from Peer Countries.
Pharmacoeconomics
December 2022
The Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, 1620 Tremont St., Suite 3030, Boston, MA, 02120, USA.
The USA pays more for brand-name prescription drugs than any other country and new legislation from August 2022 gives Medicare the authority to directly negotiate certain drug prices with manufacturers starting in 2026-something the federal insurer had been prohibited from doing for its prior history. As the USA prepares for negotiations, we therefore surveyed how comparable industrialized countries use statutory requirements and procedures to negotiate brand-name drug prices. Guidance documents, regulations, government and academic publications were reviewed to identify the process of negotiating drug prices in peer countries that have been cited as potential examples for US payment reform: Australia, Canada, France, Germany, and the UK.
View Article and Find Full Text PDFNew Drugs to Treat ADHD: Opportunities and Challenges in Research and Development.
Curr Top Behav Neurosci
August 2022
DevelRx Ltd, Nottingham, UK.
Since the landmark MTA (Multimodal Treatment of ADHD) trial unequivocally demonstrated the efficacy of methylphenidate, catecholaminergic drugs, especially stimulants, have been the therapeutic mainstay in treatment of Attention-Deficit Hyperactivity Disorder (ADHD). We review the new drugs which have entered the ADHD formulary. The lessons learned from drug-candidates that have succeeded in clinical trials together with those that have not have also been considered.
View Article and Find Full Text PDFSchizophrenia population health management: perspectives of and lessons learned from population health decision makers.
J Manag Care Spec Pharm
October 2021
University of Pennsylvania and the Leonard Davis Institute of Health Economics, Philadelphia, PA.
Despite therapeutic advances for patients with schizophrenia, improving patient outcomes and reducing the cost of care continue to challenge formulary decision makers. To (1) understand the perspectives of formulary decision makers on challenges to optimal schizophrenia population management and (2) identify best practices and recommendations for mitigating these challenges. This mixed-methods study, conducted in a double-blind manner, comprised in-depth telephone interviews with formulary decision makers from February through May 2020, and a web-based follow-on survey that was sent to all participants in October 2020.
View Article and Find Full Text PDFTreating an Epidemic During a Pandemic: Experience Treating Opioid Use Disorder at the Baltimore Convention Center Field Hospital.
Disaster Med Public Health Prep
October 2022
Division of Hospital Medicine, Johns Hopkins Bayview Medical Center, Baltimore, MD, USA.
During the COVID-19 pandemic, access to addiction treatment has plummeted. At the same time, patients with opioid use disorder are at higher risk of COVID-19 infection and experience worse outcomes. The Baltimore Convention Center Field Hospital (BCCFH), a state-run COVID-19 disaster hospital operated by Johns Hopkins Medicine and the University of Maryland Medical System, continues to operate 14 months into the pandemic to serve as an overflow unit for the state's hospitals.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!